By Colin Kellaher
Bionomics shares nearly quadrupled in early trading Thursday after the biotechnology company reported a successful study of its lead drug candidate in post-traumatic stress disorder.
Shares of the Australia-based company were recently changing hands at $3.89, up almost four-fold.
Bionomics said the Phase 2b study met its primary endpoint, showing BNC210 treatment led to a statistically significant reduction at 12 weeks in total symptom severity of PTSD, a psychiatric condition that occurs in people who have experienced or witnessed a traumatic event, series of events or set of circumstances.
The company said BNC210 also showed statistically significant improvement in secondary endpoints in depressive symptoms and sleep.
Bionomics said it plans to engage with the U.S. Food and Drug Administration to discuss plans for moving BNC210 into registrational studies for PTSD, adding that it recently held what it believes was a successful, Phase 3-enabling meeting with the agency for the advancement of BNC210 into registrational studies for the acute treatment of social anxiety disorder.
Write to Colin Kellaher at [email protected]
Read the full article here
